Titration | Jotup

Safeguard DNA Diagnostics Launches Rhinostics Dry Collection Swabs for COVID Testing as Primary Collection Devices for Its Laboratories in the Philippines

Retrieved on:

Wednesday, June 9, 2021

Science, Biotechnology, Research, Medical Supplies, General Health, Health, Medical devices, Infectious diseases, Natural sciences, Laboratory techniques, Chemistry, Physical sciences, Assay, Biochemistry, Titration, Swab

Safeguard DNA Diagnostics Inc, SDDI, one of the largest chains of infectious disease laboratories in the Philippines, has introduced COVID sample collection using the Rhinostics dry nasal and nasopharyngeal collection swabs.

Key Points:

Safeguard DNA Diagnostics Inc, SDDI, one of the largest chains of infectious disease laboratories in the Philippines, has introduced COVID sample collection using the Rhinostics dry nasal and nasopharyngeal collection swabs.
View the full release here: https://www.businesswire.com/news/home/20210609005070/en/
Rhinostics innovative dry collection swabs offer comfortable nasal or nasoharyngeal collection, dry shipment, and sample concentration for better assay performance.
The dry swabs are more robust and offer lower risk for contamination during collection and transport than VTM and saliva collection devices.
The Rhinostics suite of collection products are registered as Class I exempt medical devices with the FDA and are available for purchase.

Worldwide Cell-Based Assays Industry to 2026 - Featuring Charles River Laboratories, Danaher and Lonza Among Others - ResearchAndMarkets.com

Retrieved on:

Thursday, May 27, 2021

Health, Biotechnology, Natural sciences, Assay, Biochemistry, Titration, Biotechnology

Then further based on end-users, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, and Contract Research Organizations.

Key Points:

Then further based on end-users, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, and Contract Research Organizations.
This is due to the increasing demand for new drugs to globally treat various diseases among the rising elderly population.
In the regional market of cell-based assays, the North American region has occupied the market's substantial share.
Cell-based assays occupy various advantages over conventional biochemical assays and animal models, and these advantages have majorly driven the rising demand for these assays in the present years.

ProMIS Neurosciences initiates commercialization of COVID-19 serology assay

Retrieved on:

Tuesday, May 25, 2021

Medical specialties, Zoonoses, Medicine, Clinical medicine, Immunologic tests, Laboratory techniques, Assay, Biochemistry, Titration, ELISA, COVID-19, Middle East respiratory syndrome–related coronavirus

I am delighted to lead this opportunity on behalf of ProMIS Neurosciences, stated Owen Dempsey.

Key Points:

I am delighted to lead this opportunity on behalf of ProMIS Neurosciences, stated Owen Dempsey.
Our initial focus will be on commercialization to the medical and public health community, vaccine developers, pharmaceutical companies, governmental agencies and other organizations.
This advanced serology test developed by ProMIS Neurosciences measures not only serum antibodies to SARS-CoV-2, the novel coronavirus causing COVID-19, but also their protective activity against infection.
Additional variants can be added to the assay as they are identified.The assay utilizes an advanced, high-throughput, sensitive and accurate surface plasmon resonance (SPR) technology as opposed to traditionalELISA (enzyme-linked immunosorbent assay) methods.

New Found Intercepts 146.2 g/t Au over 25.6m in 65m step-out to South at Keats, Extends High-Grade Zone to 425m Down-Plunge

Retrieved on:

Friday, May 21, 2021

Physical sciences, Mineral economics, Chemistry, Assay, Biochemistry, Titration, Drill, Cutoff grade, Quality assurance, Economic sectors

Intervals are calculated at a 1 g/t Au cut-off grade; grades have not been capped in the averaging.

Key Points:

Intervals are calculated at a 1 g/t Au cut-off grade; grades have not been capped in the averaging.
Assays are uncut, and calculated intervals are reported over a minimum length of 2 meters using a lower cut-off of 1.0 g/t Au.
Standards and blanks are included with every 20 samples for Quality Assurance/Quality Control purposes by the Company as well as the lab.
Seven rigs are currently in operation at Queensway with the drill count planned to increase to ten rigs by Q2 2021.

$17.7 Billion Cell-based Assay Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2016-2020 & 2021-2026 - ResearchAndMarkets.com

Retrieved on:

Friday, May 21, 2021

Science, Health, Other Science, Other Health, Laboratory techniques, Natural sciences, Physical sciences, Chemistry, Drug discovery, Alternatives to animal testing, Assay, Biochemistry, Titration, High-throughput screening, In vitro

Looking forward, the publisher expects the market to exhibit strong growth during 2021-2026.\nCell-based assays refer to any experiment that use live cells.

Key Points:

Looking forward, the publisher expects the market to exhibit strong growth during 2021-2026.\nCell-based assays refer to any experiment that use live cells.
which still have large unmet needs and have led to continuous investments in R&D.
In addition, an increase in the adoption of the cell-based assay techniques for high throughput screening methods like toxicity studies, drug screening, in vitro testing, etc.
are further driving this market.\nBased on the product and services, the market has been segmented as consumables, instruments, services and software.

PerkinElmer Expands Cell Biology Leadership with Agreement to Acquire Nexcelom Bioscience

Retrieved on:

Wednesday, May 12, 2021

Biotechnology, Medical devices, Health, Genetics, Pharmaceutical, Laboratory techniques, Natural sciences, Chemistry, Physical sciences, Assay, Biochemistry, Titration, Cell counting, PerkinElmer, Nexcelom, PERKINELMER, NEXCELOM

(NYSE: PKI) is pleased to announce it has entered into an agreement to acquire Nexcelom Bioscience for $260 Million in cash.

Key Points:

(NYSE: PKI) is pleased to announce it has entered into an agreement to acquire Nexcelom Bioscience for $260 Million in cash.
Peter Li, president and chief executive officer of Nexcelom added, \xe2\x80\x9cOur team is very excited to be joining forces with PerkinElmer to help scientists resolve some of today\xe2\x80\x99s most pressing health challenges through modernizing cell based assays using the most advanced cell models.
We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise.
Founded in 2003 and currently owned by its founders and Ampersand Capital Partners, Nexcelom delivers innovative, fit-for-purpose, accurate cell counting solutions that are critical for advanced therapeutic modalities such as cell and gene therapy.

Immuno-Oncology Assays Market by Product & Service, Technology, Cancer Indications and Application - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on:

Tuesday, May 11, 2021

Health, Oncology, Natural sciences, Chemistry, Physical sciences, Biotechnology, Assay, Biochemistry, Titration, Monoclonal antibody

In 2020, the consumables segment accounted for the highest growth rate in the immuno-oncology assays market.

Key Points:

In 2020, the consumables segment accounted for the highest growth rate in the immuno-oncology assays market.
This can be attributed to the rising prominence of biomarker-based drug development.\nThe global immuno-oncology assays market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The Asia Pacific region is projected to register the highest CAGR during the forecast period.
Factors such as the growing number of CROs in the region and the increasing awareness about the early detection of cancer are driving the growth of the immuno-oncology assays market in this region.\n'

White Metal Expands Bench Zone, Extends Strike Potential to 2.1 km and Plans for Additional Drilling at the Tower Stock Gold Project, Ontario

Retrieved on:

Tuesday, May 11, 2021

Chemistry, Physical sciences, Natural sciences, Laboratory techniques, Gold, Silver, Assay, Biochemistry, Titration, Metallurgical assay, Drilling

b'Thunder Bay, Ontario--(Newsfile Corp. - May 11, 2021) - White Metal Resources Corp. (TSXV: WHM) ("White Metal" or the "Company") has received the final gold assay results from the Phase 1 2021 winter drilling program.

Key Points:

b'Thunder Bay, Ontario--(Newsfile Corp. - May 11, 2021) - White Metal Resources Corp. (TSXV: WHM) ("White Metal" or the "Company") has received the final gold assay results from the Phase 1 2021 winter drilling program.
Core assays from the 2021 drilling program clearly indicate the excellent potential for the Tower Stock Gold Project (the" Project" or the "Property"), which in addition to historical core assays show a broad horizon of low grade gold mineralization that spans for over 2.1 kilometres.
Including the 800+ metre gold zone, we now have approximately 2.1 km of aggregate strike length that will require substantial drilling.
These positive results clearly demonstrates that the Bench Zone is open at depth and along strike to the northwest, southwest, and southeast.\nTable 1.

Applied DNA and Evvivax Announce that LinearDNA™ COVID-19 Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines

Retrieved on:

Thursday, May 6, 2021

Testing showed that neutralizing titers were detected in feline sera with a geometric mean titer for the cohort of 398.

Key Points:

Testing showed that neutralizing titers were detected in feline sera with a geometric mean titer for the cohort of 398.
The average NAb titer results post-booster exceeded the three- to four-fold enhancement previously predicted by the Company.
James A. Hayward, president and CEO, Applied DNA, said, \xe2\x80\x9cThese data are very exciting because they are produced with infectious, functional virus.
The LinearDNA vaccine candidate, produced by scalable PCR-based manufacturing, yields an extremely pure product, was freeze-dried, shipped without refrigeration, and contains no excipients.

Global Multiplexed Diagnostics Market (2021 to 2029) - Featuring Agilent Technologies, BioMerieux and Hologic Among Others - ResearchAndMarkets.com

Retrieved on:

Thursday, April 29, 2021

Health, Other Health, Natural sciences, Assay, Biochemistry, Titration, Multiplexing, Agilent Technologies, Companies, Technology

Global multiplexed diagnostics market comprise of reagent and consumables, and analyzers.

Key Points:

Global multiplexed diagnostics market comprise of reagent and consumables, and analyzers.
This report includes a comprehensive market analysis of the global multiplexed diagnostics market for the period 2019 - 2029.
Based on product type, global multiplexed diagnostics market is segmented into reagents & consumables, and analyzers.
Based on technology, global multiplexed diagnostics market is segmented into low density multiplexed assays, medium density multiplexed assays, high density multiplexed assays, very high density multiplexed assays, and next-generation sequencing assays.